source
- FDA approves Hibsago, first antisense therapy for chronic hepatitis BThe U.S. Food and Drug Administration has approved Hibsago (bepirovirsen) injection to be used alongside existing antiviral therapy for chronic hepatitis B virus infection in certain adults without…
- Patients stop meds for deeper reasons than forgetfulness, pharmacist saysMarcela Gottschald, a pharmacist and journalist, reflects on her early assumption that patients missed doses mainly because they forgot, were frustrated by side effects, or lacked understanding of…